Posted by Michael Wonder on 22 Dec 2022
FDA approves new HIV drug for adults with limited treatment options
22 December 2022 - Today, the US FDA approved Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients living with human immunodeficiency virus type 1 (HIV-1), whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations.
After the starting dose is completed, Sunlenca is administered as subcutaneous injections once every six months, allowing convenient dosing for patients.
